CHEK2 and ovarian carcinoma: While targeted treatments for ovarian cancer patients with CHEK2 mutations have not been prospectively confirmed, the presence of a DNA repair deficiency is in accordance with known hallmarks of cancer, and highlights possible utility of platinum or poly (ADP‐ribose) polymerase inhibitor (PARPi).